Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GLAXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GSK PLC (GLAXF) filings document foreign-issuer disclosures for a global biopharma company registered in England and Wales. The record centers on Form 6-K current reports furnished under the Exchange Act, including announcements on product collaborations, capital-return programs, annual general meeting voting results, remuneration matters, board elections, and transaction notifications involving American Depositary Shares.
The filings also describe GSK's securities framework, including ordinary shares and ADS instruments, share repurchases and treasury-share treatment, PDMR transaction reporting, and governance resolutions connected with annual reporting and shareholder approvals. Product-related reports identify bepirovirsen in chronic hepatitis B and outline regulatory, quality, pharmacovigilance, commercial access, and global medical-strategy responsibilities associated with collaboration arrangements.
GSK plc reports that it bought back 516,000 of its ordinary shares on 9 March 2026 through BNP Paribas SA under its existing non-discretionary share buyback programme. The volume-weighted average price was 2,028.51p per share, within a range of 1,989.00p to 2,047.00p.
The shares purchased will be held as treasury shares. Since 17 February 2026, GSK has bought 7,672,000 ordinary shares under this programme. After this transaction, it holds 247,563,094 shares in treasury and has 4,068,605,728 ordinary shares in issue, which equals 4,068,605,728 voting rights.
GSK confirms that, following these purchases, the percentage of voting rights attributable to treasury shares is 6.08%, a figure shareholders may use when assessing notification thresholds under the UK Financial Conduct Authority’s disclosure and transparency rules.
GSK plc reports that it bought back 516,000 of its ordinary shares on 9 March 2026 through BNP Paribas SA under its existing non-discretionary share buyback programme. The volume-weighted average price was 2,028.51p per share, within a range of 1,989.00p to 2,047.00p.
The shares purchased will be held as treasury shares. Since 17 February 2026, GSK has bought 7,672,000 ordinary shares under this programme. After this transaction, it holds 247,563,094 shares in treasury and has 4,068,605,728 ordinary shares in issue, which equals 4,068,605,728 voting rights.
GSK confirms that, following these purchases, the percentage of voting rights attributable to treasury shares is 6.08%, a figure shareholders may use when assessing notification thresholds under the UK Financial Conduct Authority’s disclosure and transparency rules.
GSK plc reported a change in its Board committee membership. Effective 9 March 2026, Elizabeth McKee Anderson has been appointed as a member of the Corporate Responsibility Committee. She will serve on this committee in addition to her existing roles on the Audit & Risk and Remuneration committees.
GSK plc reported a change in its Board committee membership. Effective 9 March 2026, Elizabeth McKee Anderson has been appointed as a member of the Corporate Responsibility Committee. She will serve on this committee in addition to her existing roles on the Audit & Risk and Remuneration committees.
GSK plc has signed a licence agreement granting Alfasigma worldwide exclusive rights to develop, manufacture and commercialise linerixibat, an investigational IBAT inhibitor for cholestatic pruritus in primary biliary cholangitis (PBC).
GSK will receive an upfront payment of $300 million, plus $100 million upon US FDA approval, $20 million upon EU and UK approvals, and up to $270 million in sales-based milestones, along with tiered double-digit royalties on global net sales. Linerixibat has positive phase III GLISTEN data and is under regulatory review in several major markets but is not yet approved anywhere. The transaction remains subject to customary conditions, including regulatory clearances such as under the US Hart-Scott-Rodino Act.
GSK plc has signed a licence agreement granting Alfasigma worldwide exclusive rights to develop, manufacture and commercialise linerixibat, an investigational IBAT inhibitor for cholestatic pruritus in primary biliary cholangitis (PBC).
GSK will receive an upfront payment of $300 million, plus $100 million upon US FDA approval, $20 million upon EU and UK approvals, and up to $270 million in sales-based milestones, along with tiered double-digit royalties on global net sales. Linerixibat has positive phase III GLISTEN data and is under regulatory review in several major markets but is not yet approved anywhere. The transaction remains subject to customary conditions, including regulatory clearances such as under the US Hart-Scott-Rodino Act.
GSK plc reports it repurchased 690,000 ordinary shares of 31¼ pence each on 06 March 2026 through BNP Paribas under its existing share buyback programme. The lowest price paid was 2,029.00p, the highest was 2,080.00p, and the volume‑weighted average price was 2,048.95p per share.
The purchased shares will be held as treasury shares. Since 17 February 2026, GSK has bought 7,156,000 ordinary shares. After this transaction, it holds 247,047,094 shares in treasury and has 4,069,121,728 ordinary shares in issue, which is also the total number of voting rights.
The company states that, in line with DTR 5.5.1R, treasury shares represent 6.07% of voting rights. The filing also provides a detailed schedule of purchases by trading venue and individual trades on the London Stock Exchange and CBOE Europe order books.
GSK plc reports it repurchased 690,000 ordinary shares of 31¼ pence each on 06 March 2026 through BNP Paribas under its existing share buyback programme. The lowest price paid was 2,029.00p, the highest was 2,080.00p, and the volume‑weighted average price was 2,048.95p per share.
The purchased shares will be held as treasury shares. Since 17 February 2026, GSK has bought 7,156,000 ordinary shares. After this transaction, it holds 247,047,094 shares in treasury and has 4,069,121,728 ordinary shares in issue, which is also the total number of voting rights.
The company states that, in line with DTR 5.5.1R, treasury shares represent 6.07% of voting rights. The filing also provides a detailed schedule of purchases by trading venue and individual trades on the London Stock Exchange and CBOE Europe order books.
GSK plc has filed its 2025 Annual Report on Form 20-F with the US Securities and Exchange Commission, providing audited financial statements for the year ended 31 December 2025.
The report is available online on both GSK’s annual report website and the SEC’s website. A hard copy of the 2025 Annual Report and the Notice of Annual General Meeting is expected to be available on or about 25 March 2026, and shareholders can request free hard copies of the complete audited financial statements from GSK’s UK registrar or its US ADR depositary.
GSK plc has filed its 2025 Annual Report on Form 20-F with the US Securities and Exchange Commission, providing audited financial statements for the year ended 31 December 2025.
The report is available online on both GSK’s annual report website and the SEC’s website. A hard copy of the 2025 Annual Report and the Notice of Annual General Meeting is expected to be available on or about 25 March 2026, and shareholders can request free hard copies of the complete audited financial statements from GSK’s UK registrar or its US ADR depositary.
GSK plc filed its 2025 Form 20-F annual report, highlighting strong growth and major pipeline progress. Sales exceeded £32 billion, up 4% at reported rates and 7% at constant exchange. Total operating profit rose 97%, while core operating profit grew 7% reported and 11% at constant exchange.
Total earnings per share more than doubled, and core EPS increased 8% reported and 12% at constant exchange. Cash generation reached £8.9 billion, supporting a dividend of 66p per share, up from 61p. R&D spending was £7.5 billion, up 18% reported, backing 58 pipeline assets and five key 2025 approvals including Exdensur, Blenrep, Nucala, Blujepa and Penmenvy.
The report details a leadership transition, with Emma Walmsley stepping down as CEO at year-end and former Chief Commercial Officer Luke Miels taking over. Management emphasizes executing launches, advancing late-stage assets in respiratory, oncology, HIV and hepatology, and using AI and business development to drive growth toward and beyond 2031.
GSK plc filed its 2025 Form 20-F annual report, highlighting strong growth and major pipeline progress. Sales exceeded £32 billion, up 4% at reported rates and 7% at constant exchange. Total operating profit rose 97%, while core operating profit grew 7% reported and 11% at constant exchange.
Total earnings per share more than doubled, and core EPS increased 8% reported and 12% at constant exchange. Cash generation reached £8.9 billion, supporting a dividend of 66p per share, up from 61p. R&D spending was £7.5 billion, up 18% reported, backing 58 pipeline assets and five key 2025 approvals including Exdensur, Blenrep, Nucala, Blujepa and Penmenvy.
The report details a leadership transition, with Emma Walmsley stepping down as CEO at year-end and former Chief Commercial Officer Luke Miels taking over. Management emphasizes executing launches, advancing late-stage assets in respiratory, oncology, HIV and hepatology, and using AI and business development to drive growth toward and beyond 2031.
GSK plc reports that on 05 March 2026 it repurchased 650,000 ordinary shares at prices between 2,072.00p and 2,135.00p, with a volume‑weighted average price of 2,102.05p. These shares will be held as treasury shares under its existing buyback programme operated via BNP Paribas.
Since 17 February 2026, GSK has bought back 6,466,000 ordinary shares. After this latest transaction, it holds 246,357,094 shares in treasury and has 4,069,805,394 ordinary shares in issue, which is also the total number of voting rights. Treasury shares now represent 6.05% of voting rights.
GSK plc reports that on 05 March 2026 it repurchased 650,000 ordinary shares at prices between 2,072.00p and 2,135.00p, with a volume‑weighted average price of 2,102.05p. These shares will be held as treasury shares under its existing buyback programme operated via BNP Paribas.
Since 17 February 2026, GSK has bought back 6,466,000 ordinary shares. After this latest transaction, it holds 246,357,094 shares in treasury and has 4,069,805,394 ordinary shares in issue, which is also the total number of voting rights. Treasury shares now represent 6.05% of voting rights.
GSK plc has published its Annual Report 2025 for the year ended 31 December 2025 on its dedicated website. The report has also been submitted to the UK Financial Conduct Authority’s National Storage Mechanism for public inspection in accordance with UK listing and transparency rules.
Shareholders who have opted for paper communications will receive hard copies of the Annual Report 2025 and the 2026 Annual General Meeting notice on or around 25 March 2026, with the AGM notice made available to all other shareholders on the same date. GSK describes itself as a global biopharma company focused on uniting science, technology, and talent to get ahead of disease.
GSK plc has published its Annual Report 2025 for the year ended 31 December 2025 on its dedicated website. The report has also been submitted to the UK Financial Conduct Authority’s National Storage Mechanism for public inspection in accordance with UK listing and transparency rules.
Shareholders who have opted for paper communications will receive hard copies of the Annual Report 2025 and the 2026 Annual General Meeting notice on or around 25 March 2026, with the AGM notice made available to all other shareholders on the same date. GSK describes itself as a global biopharma company focused on uniting science, technology, and talent to get ahead of disease.
GSK plc reports that on 04 March 2026 it repurchased 550,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme, at prices between 2,109.00p and 2,149.00p per share and a volume‑weighted average of 2,129.91p.
The shares will be held as treasury shares. Since 17 February 2026, GSK has bought 5,816,000 ordinary shares. After this transaction, it holds 245,707,094 shares in treasury and has 4,070,455,394 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 6.04% of voting rights.
GSK plc reports that on 04 March 2026 it repurchased 550,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme, at prices between 2,109.00p and 2,149.00p per share and a volume‑weighted average of 2,129.91p.
The shares will be held as treasury shares. Since 17 February 2026, GSK has bought 5,816,000 ordinary shares. After this transaction, it holds 245,707,094 shares in treasury and has 4,070,455,394 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 6.04% of voting rights.